Cingulate Announces Presentation of Full Trial Results from Phase 3 Adult Efficacy and Safety Trial of CTx-1301 (dexmethylphenidate) for ADHD at Psych Congress 2023
September 05, 2023 08:00 ET
|
Cingulate Inc.
KANSAS CITY, Kan., Sept. 05, 2023 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform...
Global Drug Device Combination Products Market 2023-2028: Boston Scientific Corp and Becton, Dickinson and Company: Innovating Drug Device Combination Solutions
September 05, 2023 06:28 ET
|
Research and Markets
Dublin, Sept. 05, 2023 (GLOBE NEWSWIRE) -- The "Drug Device Combination Products Market Size & Share Analysis - Growth Trends & Forecasts (2023 - 2028)" report has been added to ...
RNAi Drug Delivery Technologies and Global Market Analysis Report 2023: Historic Market Revenue from 2020 to 2022, Estimates for 2023, and CAGR Projections through to 2028
August 29, 2023 07:08 ET
|
Research and Markets
Dublin, Aug. 29, 2023 (GLOBE NEWSWIRE) -- The "RNAi Drug Delivery: Technologies and Global Markets" report has been added to ResearchAndMarkets.com's offering. The global RNAi drug delivery...
Key Players F. Hoffmann-La Roche, 3M, Pfizer, and More Fuel Global Drug Delivery Devices Market Reaching $115.09 Billion by 2027
August 16, 2023 04:43 ET
|
Research and Markets
Dublin, Aug. 16, 2023 (GLOBE NEWSWIRE) -- The "Drug Delivery Devices Global Market Report 2023" report has been added to ResearchAndMarkets.com's offering. This report provides strategists,...
Cingulate Inc. Reports Second Quarter 2023 Financial Results and Provides Clinical and Business Update
August 14, 2023 16:15 ET
|
Cingulate Inc.
Werth Family Investment Associates Provides Additional Capital InvestmentPhase 3 Adult Efficacy and Safety Trial of CTx-1301 Data ReleasedCTx-1301 Phase 3 Pediatric and Adolescent Studies Underway ...
Cingulate Announces Positive Top-Line Results from Phase 3 Adult Efficacy and Safety Trial of CTx-1301 (dexmethylphenidate) for ADHD
July 11, 2023 08:00 ET
|
Cingulate Inc.
KANSAS CITY, Kan., July 11, 2023 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform...
Cingulate Successfully Manufactures Clinical Supply – Initiation of Pediatric Phase 3 Studies to Commence in July and August
June 29, 2023 08:00 ET
|
Cingulate Inc.
KANSAS CITY, Kan., June 29, 2023 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform...
Cingulate to Participate in the Healthcare Virtual Conference Part II Presented by Maxim Group and Hosted by M-Vest
June 14, 2023 15:45 ET
|
Cingulate Inc.
KANSAS CITY, Kan., June 14, 2023 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform...
Cingulate Completes Phase 3 Adult Trial of CTx-1301 (dexmethylphenidate) for ADHD
June 08, 2023 07:00 ET
|
Cingulate Inc.
Study Assessed Onset and Duration of CTx-1301 in Adults, Results Expected 3Q 2023 Pivotal Phase 3 Trials in Pediatric/Adolescent Patients on Schedule for 3Q 2023 Initiation KANSAS CITY, Kan., June ...
Global Drug Delivery Partnering Deal Terms and Agreements Analysis Report 2023: Review Drug Delivery Deal Trends, Key Players, & Top Deal Values for Deals Signed Since 2016
June 06, 2023 03:13 ET
|
Research and Markets
Dublin, June 06, 2023 (GLOBE NEWSWIRE) -- The "Global Drug Delivery Partnering Terms and Agreements 2016-2023" report has been added to ResearchAndMarkets.com's offering.The Global Drug delivery...